Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
Classement en actions
#3610
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
Prix de l'action
$3.74
Capitalisation boursière
$4.73B
Changement (1 jour)
0.74%
Changement (1 an)
-51.90%
Pays
CN
Échange Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Catégorie
Healthcare
Ratio P/B pour Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Ratio P/B au October 2026 TTM : 2.70
Selon les derniers rapports financiers et le cours de l'action de Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., le ratio cours/valeur comptable actuel (TTM) est 2.70. À la fin de 2023, le ratio P/B était de 7.46.
Historique du ratio P/B pour Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. de 2013 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 2.70 | -64.57% |
| 2024 | 7.63 | 2.35% |
| 2023 | 7.46 | -18.64% |
| 2022 | 9.16 | -63.42% |
| 2021 | 25.05 | -9.41% |
| 2020 | 27.65 | 962.67% |
| 2019 | 2.60 | -10.83% |
| 2018 | 2.92 | -31.74% |
| 2017 | 4.28 | 0.30% |
| 2016 | 4.26 | -22.48% |
| 2015 | 5.50 | -15.25% |
| 2014 | 6.49 | -31.92% |
| 2013 | 9.53 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | 131.26% |
US
|
|
| 13.2547 | 390.37% |
US
|
|
| 4.208 | 55.68% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 128.72% |
NL
|
